News | August 23, 2024
Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
These accolades highlight our unwavering commitment to maintaining the highest safety standards
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Our centers are performing as expected or even better
Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Subscribe To Our Newsletter & Stay Updated
